Seelos Therapeutics Inc (NASDAQ:SEEL) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totalling 741,300 shares, a drop of 21.6% from the May 30th total of 945,900 shares. Based on an average daily trading volume, of 630,500 shares, the days-to-cover ratio is presently 1.2 days. Approximately 25.6% of the shares of the stock are sold short.

Seelos Therapeutics stock traded down $0.01 during trading hours on Friday, hitting $2.02. The stock had a trading volume of 125,488 shares, compared to its average volume of 657,293. Seelos Therapeutics has a one year low of $1.32 and a one year high of $13.95. The business has a 50 day moving average of $2.30.

Seelos Therapeutics (NASDAQ:SEEL) last posted its earnings results on Tuesday, May 21st. The company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.20). On average, equities research analysts forecast that Seelos Therapeutics will post -4.43 EPS for the current year.

Several analysts recently weighed in on the company. HC Wainwright set a $12.00 price objective on IMV and gave the company a “buy” rating in a research note on Friday, May 10th. Roth Capital set a $10.00 price objective on Savara and gave the company a “hold” rating in a research note on Tuesday, May 14th.

About Seelos Therapeutics

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.

See Also: Quiet Period

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with's FREE daily email newsletter.